WP2
Radionuclide targeted therapy and imaging in Glioblastoma
The plasticity of GB tumor cells and their ability to infiltrate adjoining brain tissue limits the effectiveness of current cancer therapies. Microglia plays an important role in GB progression. Inhibition of EGFR and CSF-1R decreases microglia-stimulated invasion of GB cells. Specific radiopharmaceuticals targeting EGFR or CSF-1R will be developed (WP3/Bergen) and applied as (i) diagnostic tool (11C, 18F) and (ii) radionuclide targeted therapy with radiometals (radiotherapeutics) combined with chemo- and external radiotherapy. To evaluate its EGFR or CSF-1R affinity and selectivity, radiopharmaceuticals will be tested by in vivo PET/SPECT/MR in healthy animals and orthotopic animals models of GB (UNN).
Project Staff
Marcel Lindemann
Researcher (Postdoctoral Fellow)Department of Clinical Medicine
Yngve Guttormsen
Research Fellow (PhD Candidate)Department of Clinical Medicine
Collaboration Partners
|
Researcher/Group |
Affiliation |
|
Principal InvestigatorsMathias Kranz, PhD Mathias.Kranz@unn.no Researcher University Hospital of North Norway (UNN) Rune Sundset Assoc. Prof., MD, PhD Rune.Sundset@unn.no Rune.Sundset@uit.no Leader, Nuclear Medicine and Radiation Biology Research Group Leader, Preclinical Core Facility Department of Clinical Medicine UiT The Arctic University of Norway Leader, PET Imaging Center University Hospital of North Norway (UNN) |
